A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 9, 2010, Pages 1691-1695

  Nakamae, Hirohisa ^a   Terada, Yoshiki ^a   Nakane, Takahiko ^a   Koh, Hideo ^a   Nakamae, Mika ^a   Aimoto, Ran ^a   Hirose, Asao ^a   Hayashi, Yoshiki ^a   Nishimoto, Mitsutaka ^a   Inoue, Eri ^a   Yoshimura, Takuro ^a   Inoue, Atsushi ^a   Koh, Ki Ryang ^a   Yamane, Takahisa ^a   Hino, Masayuki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Intravenous busulfan; Modified myeloablative conditioning regimen; Total lymphoid irradiation (TLI)

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LEUKEMIA; CLINICAL ARTICLE; FOLLOW UP; HUMAN; LEUKEMIA; LYMPH NODE IRRADIATION; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; RADIATION DOSE;

EID: 79960796354     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Weiner RS, Bortin MM, Gale RP, et al: Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med 104(2): 168-175, 1986.
2. Giorgiani G, Bozzola M, Locatelli F, et al: Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood 86(2): 825-831, 1995.
3. Dix SP, Wingard JR, Mullins RE, et al: Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17(2): 225-230, 1996.
4. Pawlowska AB, Blazar BR, Angelucci E, et al: Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 20(11): 915-920, 1997.
5. Andersson BS, Thall PF, Madden T, et al: Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i. v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 8(9): 477-485, 2002.
6. Ringden O, Ruutu T, Remberger M, et al: A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 83(9): 2723-2730, 1994. (Pubitemid 24135867)
7. Andersson BS, Kashyap A, Gian V, et al: Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8(3): 145-154, 2002.
8. Giralt S, Estey E, Albitar M, et al: Engraftment of allogeneic hematopoietic progenitor cells with purine analogcontaining chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89(12): 4531-4536, 1997.
9. Khouri IF, Keating M, Körbling M, et al: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16(8): 2817-2824, 1998.
10. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3): 756-763, 1998.
11. Champlin R, Khouri I, Shimoni A, et al: Harnessing graft-versus- malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111(1): 18-29, 2000.
12. Giralt S, Thall PF, Khouri I, et al: Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97(3): 631-637, 2001.
13. Corradini P, Tarella C, Olivieri A, et al: Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99(1): 75-82, 2002.
14. Shimoni A, Hardan I, Shem-Tov N, et al: Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20(2): 322-328, 2006.
15. Giralt S, Ballen K, Rizzo D, et al: Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15(3): 367-369, 2009.
16. Kanda Y, Sakamaki H, Sao H, et al: Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor. Biol Blood Marrow Transplant 11(11): 881-889, 2005. (Pubitemid 41645641)
17. Kato K, Khaled Y, Braun T, et al: Superior disease-free survival in acute myelogenous leukemia/myelodysplastic syndrome receiving reduced-intensity allogeneic hematopoietic stem cell transplantation from unrelated donors using fludarabine, busulfan, and total lymphoid irradiation. Biol Blood Marrow Transplant 13(2): suppl 131, 2007.